Infliximab, subcutaneous anti-TNF agents, and ustekinumab show comparable effectiveness as second-line therapies in patients with ulcerative colitis after vedolizumab failure.
Medscape News UK
Source link : https://www.medscape.com/viewarticle/are-second%E2%80%91line-therapies-after-vedolizumab-failure-2026a10009x6?src=rss
Author :
Publish date : 2026-04-03 12:00:00
Copyright for syndicated content belongs to the linked Source.